Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system
Wanlong Lin, Jiabing Xu, Yu‐Fang Liao, Xiuxian Lin, Jianhui Yang, Wei Zhuang
Topics & Concepts
MedicinePharmacovigilanceInternal medicineInterstitial lung diseaseAntibody-drug conjugateGemtuzumab ozogamicinAdverse effectBrentuximab vedotinAdverse Event Reporting SystemOncologyLung cancerOdds ratioPharmacologyLungImmunologyAntibodyMonoclonal antibodyGeneticsStem cellHodgkin lymphomaCD33CD34BiologyLymphomaHER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis